

CLAIM LISTING

1-14. (Canceled)

15. (Previously Presented) A method of treating systemic lupus erythematosus in a human patient comprising administering to said patient an effective dose of a CD1d blocking antibody, wherein said effective dose treats said systemic lupus erythematosus in said human patient.

16. (Previously Presented) The method of Claim 15 wherein said administration inhibits a pathologic polyclonal B cell activation or class switching.

17. (Previously Presented) The method according to Claim 15, wherein said antibody is a monoclonal antibody.

18. (Previously Presented) The method according to Claim 17, wherein said monoclonal antibody is a human or humanized antibody.

19. (Previously Presented) The method according to Claim 17, wherein said monoclonal antibody specifically binds to human CD1d.

20. (Previously Presented) The method according to Claim 15, wherein said administration is by intravenous injection.

21. (Previously Presented) A method according to Claim 15, further comprising administering to said patient a second therapeutic agent for the treatment of systemic lupus erythematosus.

22. (Previously Presented) The method of Claim 21, wherein said second therapeutic agent is a non-steroidal anti-inflammatory drug, corticosteroid, immunomodulating drug, and/or an anticoagulant.

23. (Previously Presented) A method of treating systemic lupus erythematosus in a human patient comprising administering to said patient an effective dose of a CD1d blocking antibody, wherein said effective dose treats said systemic lupus erythematosus in said human patient and inhibits a pathologic polyclonal B cell activation or class switching.

24. (Previously Presented) A method of treating systemic lupus erythematosus in a human patient comprising administering to said patient an effective dose of a CD1d blocking antibody, wherein said effective dose treats said systemic lupus erythematosus in said human patient and delays the onset of proteinuria.

25. (Previously Presented) The method according to Claim 24, wherein said administering to said patient an effective dose of a CD1d blocking antibody reduces the levels of serum IgG and anti-dsDNA IgG.

26. (Previously Presented) The method according to Claim 24, wherein said administering to said patient an effective dose of a CD1d blocking antibody prolongs survival of said patient.